Description: Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Its chemical name is (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.
Pharmacological effects: Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications.
Indications: Voglibose is an oral antidiabetic medication used to lower postprandial blood glucose levels (postprandial hyperglycemia) in people with diabetes mellitus. It is an alpha-glucosidase inhibitor that delays the digestion and absorption of sugar.
Adverse reaction: Voglibose can cause side effects such as diarrhea, flatulence, skin reactions, and hypoglycemia.
